Xenon Pharmaceuticals stock hits all-time high at 63.96 USD
Xenon Pharmaceuticals Inc. (XENE) recently saw its stock price reach an all-time high of $63.96, surpassing its 52-week high and reflecting a 1-year gain of over 102%. This strong performance comes despite reporting zero revenue in Q1 2026, though EPS exceeded forecasts. Analysts maintain a "strong buy" consensus with a high price target of $100.
Enterprise value to revenue forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE
This article focuses on the "Enterprise value to revenue forward" metric for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). Although the provided content is largely navigational and informational about the TradingView platform, it specifically highlights this financial ratio within the context of Xenon Pharmaceuticals' stock performance.
Price to book forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE
This article displays the "Price to book forward" for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). The content is primarily a data point with no further analysis or discussion. It indicates the latest value for this financial metric for the specified company.
We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate
Xenon Pharmaceuticals (NASDAQ:XENE) has a cash runway of 3.6 years based on its US$1.1 billion cash reserves in March 2026 and a US$307 million cash burn rate. While its cash burn increased by 54% last year, analysts project the company will break even within approximately four years. This long cash runway and manageable cash burn relative to market capitalization suggest shareholders should not be overly concerned about the company's financial stability.
XENE - Xenon Pharmaceuticals Inc Volatility & Greeks
This article provides a detailed financial overview of Xenon Pharmaceuticals Inc. (XENE), including its latest stock performance, key financial metrics, volatility indicators, and analyst recommendations. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider and institutional ownership data.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 20,200 share options and 11,850 restricted share units (RSUs). These grants were approved by the Compensation Committee and are material inducements for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $60.30 and vest over four years, while RSUs vest over four years as well, both subject to continued employment.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, totaling 20,200 share options and 11,850 restricted share units (RSUs). These grants, approved by the Compensation Committee, were made to induce employment in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $60.30 and vest over four years, while the RSUs also vest over four years.
Price to earnings forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE
The article focuses on the "Price to earnings forward" financial metric for Xenon Pharmaceuticals Inc. (NASDAQ: XENE) as presented on the TradingView platform. It provides the company's stock symbol and market information, indicating that the market was closed at the time the data was accessed. The content is primarily a listing of general TradingView features and legal disclaimers.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, including share options and restricted share units (RSUs), approved by the Compensation Committee with an effective date of July 1, 2026. These grants, totaling 20,200 share options and 11,850 RSUs, were made to induce new employees to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have a 10-year term and an exercise price of $60.30, vesting over four years, while the RSUs also vest over four years based on the employee's start date and continued service.
Xenon awards new hires 20,200 options and 11,850 RSUs
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has granted equity inducement awards to four new non-officer employees, consisting of 20,200 share options and 11,850 restricted share units (RSUs). These grants, approved by the Compensation Committee, have an exercise price of $60.30 and vest over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). The company highlighted its lead molecule, azetukalner, which is in Phase 3 trials for epilepsy, MDD, and BPD, as well as early-stage programs for pain treatment.
XENE - Xenon Pharmaceuticals Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Xenon Pharmaceuticals Inc. (XENE). It includes key financial metrics, performance indicators, insider/institutional ownership details, and analyst recommendations, offering a detailed snapshot of the company's current market position and financial health.
Enterprise value to EBIT forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE
This article focuses on the enterprise value to EBIT forward for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). It appears to be a financial data point or a report generated by TradingView, a financial platform. The content primarily lists navigation and footer information related to TradingView, with minimal actual article text regarding XENE's financial metrics.
The Technical Signals Behind (XENE) That Institutions Follow
This article analyzes Xenon Pharmaceuticals Inc. (NASDAQ: XENE) using AI models to identify institutional trading signals. It highlights strong sentiment across all horizons, an exceptional risk-reward setup, and provides three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, tailored for different risk profiles and holding periods. The analysis is supported by a multi-timeframe signal breakdown for near-term, mid-term, and long-term outlooks.
Is Positive X-TOLE2 Epilepsy Data And 2026 FDA Filing Plan Altering The Investment Case For Xenon Pharmaceuticals (XENE)?
Xenon Pharmaceuticals recently announced positive Phase III X-TOLE2 results for azetukalner in focal onset seizures and plans to submit a new drug application to the FDA for this indication in Q3 2026. This progress advances azetukalner within the company's neuroscience pipeline and strengthens its investment narrative, although it also highlights the importance of successful regulatory review and managing recent share dilution from a $650 million equity raise. The article suggests this progress could lead to significant revenue and earnings growth, potentially justifying a fair value of $55.40.
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Xenon Pharmaceuticals (XENE) stock has surged 22% over the past six months, outperforming the industry's decline, driven by strong investor confidence in its neuroscience pipeline. Key to this growth is azetukalner, the company's lead asset, which showed positive phase III results for focal onset seizures and is being expanded for major depressive disorder and bipolar depression. Xenon is also advancing other early-stage neuroscience compounds.
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Xenon Pharmaceuticals (XENE) shares have increased by approximately 22% over the last six months, significantly outperforming the industry's decline. This growth is largely attributed to investor confidence in its neuroscience pipeline, especially azetukalner, which has shown promising results in Phase III trials for focal onset seizures (FOS) and is expanding into treatments for major depressive disorder (MDD) and bipolar depression (BPD). The company also has other early-stage assets, including XEN1701 and XEN1120, under development for pain indications.
Xenon Pharmaceuticals (XENE) Q4 2025 earnings summary
Xenon Pharmaceuticals released its Q4 2025 earnings, highlighting significant progress in Phase 3 clinical trials for azetukalner in epilepsy and neuropsychiatry, with NDA submission expected in 2026. The company expanded its early-stage pipeline and raised $242.2 million through ATM offerings, extending its cash runway into H2 2027. Despite increased R&D and G&A expenses leading to a higher net loss of $345.9 million for 2025, the company ended the year with $586.0 million in cash, cash equivalents, and marketable securities.
Xenon Pharmaceuticals Inc (XENE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Xenon Pharmaceuticals Inc (XENE), including its stock performance, market capitalization, and financial overview. It notes that relevant data regarding business segments, regional revenue, and profit contribution for recent fiscal years have not been disclosed by the company, though it lists Canada with a revenue of $7.50M and 0.00% proportion. The content primarily highlights the unavailability of detailed revenue segmentation data.
Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Xenon Pharmaceuticals Inc (XENE), including its major shareholders and institutional holdings. It lists the top individual shareholders like Fidelity Management & Research Company LLC and Avoro Capital Advisors LLC, as well as categorizes shareholders by type (e.g., Investment Advisor/Hedge Fund). The report also provides quarterly institutional shareholding data and lists related ETFs holding XENE stock.
Xenon Pharmaceuticals Inc (XENE) Institutional Confidence
Xenon Pharmaceuticals Inc (XENE) has an institutional confidence score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 116.66%, a 21.96% increase quarter-over-quarter. Paul Tudor Jones is the largest institutional shareholder with 534.69K shares.
Xenon Pharmaceuticals Inc (XENE) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Xenon Pharmaceuticals Inc (XENE), highlighting its current earnings forecast score, analyst ratings, and price targets. It includes a peer comparison and addresses frequently asked questions regarding expected revenue, price targets, recent EPS performance, and overall analyst sentiment, which leans towards a "Buy" trend.
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate
Xenon Pharmaceuticals (XENE) recently experienced a share price pullback, with the stock down around 3% in the past day and 4% in the last week, yet it has shown strong performance over the past year. Despite the recent dip, Simply Wall St assesses XENE as modestly undervalued at $51.34 against a fair value of $55.40, driven by its ion channel pipeline and potential in non-opioid pain relief markets. The article encourages investors to analyze the underlying financials and risk-reward profile further, especially considering the rapid changes possible in pharmaceutical valuations.
Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE
Fiera Capital Corp increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 31.9% in the fourth quarter, bringing its total holdings to 686,056 shares valued at $30.7 million. Several other institutional investors also increased their positions, indicating significant institutional ownership (95.45%) in the biopharmaceutical company. Analysts maintain a "Buy" rating for Xenon with an average price target of $77.20, while the stock recently traded around $51.21 after reporting in-line quarterly EPS.
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade
Xenon Pharmaceuticals director Gary Patou sold 1,322 shares of XENE stock at $53.14 per share on June 5, 2026. This transaction was conducted under a pre-planned Rule 10b5-1 trading plan adopted in August 2025, specifically to cover income tax obligations from the vesting of restricted stock units. After the sale, Patou directly holds 24,896 shares and indirectly holds 4,902 shares.
Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan
Xenon Pharmaceuticals Inc. director Gillian Cannon sold 1,190 common shares at an average price of $53.14 per share on June 5, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, primarily to cover income tax obligations from vested Restricted Stock Units (RSUs). After the sale, Cannon directly holds 1,455 shares.
[144] Xenon Pharmaceuticals Inc. SEC Filing
This article reports on a Form 144 SEC filing by Xenon Pharmaceuticals Inc. (XENE), detailing a proposed sale of 1,322 common shares by an insider. The filing indicates the securities were acquired on May 31, 2026, as Restricted Stock Units from the issuer. The aggregated market value of the shares to be sold is $70,052.78, with the proposed sale date being June 5, 2026, on NASDAQ.
[144] Xenon Pharmaceuticals Inc. SEC Filing
This article reports on Xenon Pharmaceuticals Inc.'s SEC Form 144 filing, which details a proposed sale of 1,190 shares of common stock with an aggregate market value of $63,058.10 by an individual on June 5, 2026. The shares were acquired through restricted stock units on May 31, 2026. The filing indicates a neutral impact and sentiment regarding the proposed sale.
Xenon Pharmaceuticals (XENE) director receives RSUs, options and nets vested shares
Xenon Pharmaceuticals director Steven Gannon reported receiving 1,593 Restricted Share Units (RSUs) vesting by June 2027 and options to purchase 10,507 common shares at $53.46, expiring in 2036. Additionally, 2,645 previously granted RSUs vested, with 1,416 shares withheld for tax obligations. After these transactions, Gannon directly holds 11,870 common shares.
Xenon Pharmaceuticals (XENE) director receives new RSUs, options and RSU vesting
Xenon Pharmaceuticals director Elizabeth A. Garofalo has received new equity awards and experienced RSU vesting. On June 1, 2026, 2,645 Restricted Share Units vested and converted into common shares. Subsequently, on June 3, 2026, Garofalo was granted 1,593 new Restricted Share Units and an option to purchase 10,507 Common Shares at an exercise price of $53.46, both of which will vest by June 1, 2027, or earlier.
Xenon Pharmaceuticals (XENE) director awarded RSUs, options and exercises RSUs
Xenon Pharmaceuticals director Patrick Machado was awarded 1,593 Restricted Share Units (RSUs) and options for 10,507 shares with an exercise price of $53.46 on June 3, 2026. Additionally, on June 1, 2026, 2,645 RSUs vested and converted into common shares. These transactions highlight equity awards and an RSU exercise, with no open-market share purchases or sales reported.
Xenon Pharmaceuticals (XENE) director awarded RSUs, options and RSUs vest into shares
Xenon Pharmaceuticals director Gillian Cannon reported receiving routine equity compensation and an option exercise. She was granted 1,593 Restricted Share Units and 10,507 share options, all subject to future vesting. Additionally, 2,645 RSUs from a previous grant on June 5, 2025, fully vested on June 1, 2026, and converted into common shares.
Xenon Pharmaceuticals (XENE) director exercises RSUs and gets new option award
Xenon Pharmaceuticals director Dawn Svoronos reported routine equity compensation activity. She exercised previously granted restricted share units (RSUs) into Common Shares, with some shares withheld for taxes, and subsequently holds 26,229 Common Shares. Additionally, she received new awards consisting of 1,593 RSUs and options for 10,507 shares, both vesting around the company's 2027 annual meeting of shareholders.
Xenon Pharmaceuticals (XENE) investors approve 2026 equity plan and pay votes
Xenon Pharmaceuticals Inc. shareholders approved a new 2026 Equity Incentive Plan, re-elected all director nominees, endorsed executive compensation in an advisory "say-on-pay" vote, and opted for annual advisory votes on executive compensation. Shareholders also reappointed PricewaterhouseCoopers LLP as the independent auditor and authorized the audit committee to determine the auditor's remuneration. These decisions were made at the annual meeting of shareholders held on June 2, 2026, with a high shareholder turnout.
Wells Fargo Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $69
Wells Fargo has reiterated its Buy rating on Xenon Pharmaceuticals (XENE.US) and maintained its target price at $69. This continued endorsement suggests confidence in the company's future performance or valuation.
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Recent Pullback And Strong Multi Year Returns
Xenon Pharmaceuticals (XENE) has seen a recent pullback despite strong multi-year returns, reporting revenue and net income growth, and trading below analyst price targets. The company is considered 3.6% undervalued with a fair value of $55.40, based on assumptions of rapid revenue expansion and improved profit margins through its ion channel pain franchise. However, this valuation depends on successful late-stage trials and competitive drug performance, suggesting a finely balanced risk-reward profile for investors.
XENE - Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
Xenon Pharmaceuticals (XENE) is positioned for long-term growth driven by its ion channel-targeted medicines for epilepsy, mood disorders, and pain. The company's lead candidate, azetukalner, is advancing in late-stage trials for epilepsy and is also being expanded into major depressive disorder and bipolar depression. Analysts project significant revenue growth for Xenon, expecting a 236.2% annual increase over the next three years, with potential profitability by 2028.
Xenon Pharmaceuticals Inc. Rings the Nasdaq Stock Market Opening Bell
Xenon Pharmaceuticals Inc., a biopharmaceutical company focused on neuroscience, celebrated its recent positive Phase 3 clinical trial results in epilepsy by ringing the Opening Bell at the Nasdaq MarketSite in Times Square. The company is making progress towards becoming a commercial biopharmaceutical entity. Ian Mortimer, President & CEO, led the ceremony.
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Recent Pullback And Strong Multi Year Returns
Xenon Pharmaceuticals (XENE) has experienced a recent pullback, though it shows strong multi-year returns and is trading below analyst price targets. The company is considered 3.6% undervalued with a fair value of $55.40, based on rapid revenue expansion and potential profit margin shifts. However, this valuation depends on successful late-stage trial results and competition, indicating a finely balanced risk/reward scenario.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to 10 new non-officer employees, totaling 32,750 share options and 19,200 restricted share units (RSUs). These grants, approved by the Compensation Committee, are material inducements for joining the company and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $54.79 and vest over four years, while the RSUs vest over the first four anniversaries of the employees' start dates.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
Xenon Pharmaceuticals announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This brief report indicates a regulatory compliance step taken by the company. Further details on the specific grants were not provided in this short news item.
XENE - Xenon Pharmaceuticals Inc Stock Price and Quote
This article provides comprehensive financial data for Xenon Pharmaceuticals Inc. (XENE), including its stock price, market capitalization, key financial ratios, and recent news. It also details analyst ratings and insider transactions, highlighting the company's focus on neuroscience-focused drug development and its pipeline for neurological disorders.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to 10 new non-officer employees, comprising 32,750 share options and 19,200 restricted share units (RSUs). These grants, approved by the Compensation Committee, were made to induce employment in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $54.79 and vest over four years, while the RSUs vest over the first four anniversaries of the employees' start dates.
J.P. Morgan Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $82
J.P. Morgan has reiterated its Buy rating on Xenon Pharmaceuticals (XENE.US) and increased its target price for the company's stock to $82. This analyst action suggests continued confidence in Xenon's financial prospects and potential for growth. Investors and market watchers may view this as a positive indicator for the biotechnology company.
Trading the Move, Not the Narrative: (XENE) Edition
This article analyzes Xenon Pharmaceuticals Inc. (XENE), highlighting divergent sentiment across different time horizons and suggesting choppy market conditions. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for various risk profiles, along with a multi-timeframe signal analysis. The analysis also identifies a significant short setup with a 32.1:1 risk-reward ratio, targeting a 9.3% downside.
Xenon Pharmaceuticals (Nasdaq:XENE) - Stock Analysis
Xenon Pharmaceuticals Inc. (XENE) is a neuroscience biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders, with its lead candidate, azetukalner, showing promising Phase 3 results for focal onset seizures and progressing towards FDA submission in Q3 2026. The company also has azetukalner in development for major depressive disorder and bipolar depression. Recent positive clinical data and analyst target price increases suggest a favorable outlook, despite the company currently being unprofitable and shareholders having faced dilution.
The Bull Case For Xenon Pharmaceuticals (XENE) Could Change Following Strong X-TOLE2 Data And FDA NDA Plans
Xenon Pharmaceuticals (XENE) recently reported strong Q1 results, with its X-TOLE2 study for azetukalner in focal onset seizures exceeding expectations. This has solidified plans for a New Drug Application (NDA) submission to the FDA in Q3 2026, potentially reshaping the investment narrative for the company. While this progress strengthens the near-term catalyst, investors should still consider the company's reliance on a single drug and ongoing losses.
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)
JPMorgan analyst Tessa Romero raised the firm's price target on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to $80 from $77, maintaining an Overweight rating. This comes after the company reported positive Q1 EPS and strong results from its X-TOLE2 study for azetukalner in focal onset seizures, supporting plans for an FDA New Drug Application in Q3 2026. The company expects its cash position to support operations into 2029 and is advancing other Phase 3 studies and new pain-focused programs.
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)
JPMorgan analyst Tessa Romero raised the price target on Xenon Pharmaceuticals (XENE) to $80 from $77, maintaining an Overweight rating, following positive Q1 EPS results and strong X-TOLE2 study data for azetukalner in focal onset seizures. Wells Fargo also increased its price target. The company plans to submit a New Drug Application to the FDA in Q3 2026 and expects its cash position to support operations into 2029.
A Look At Xenon Pharmaceuticals (XENE) Valuation After Strong Long Term Returns And Recent Momentum Cooldown
Xenon Pharmaceuticals (XENE) has shown strong long-term returns but recent momentum has cooled, leading to questions about its current valuation. Despite no revenue and ongoing losses, a narrative suggests the stock is 45.9% undervalued with a fair value of $100.00 per share, driven by its late-stage neurology programs and ambitious earnings expectations. However, this bullish outlook is contingent on successful clinical trials and avoiding shareholder dilution.
5 Best Performing Canadian Stocks So Far in 2026
This article identifies Xenon Pharmaceuticals Inc. (NASDAQ:XENE) as one of the best-performing Canadian stocks in 2026. Analysts from JPMorgan and Wells Fargo raised price targets on XENE, maintaining Overweight ratings due to positive Phase 3 data for azetukalner in focal onset seizures. The company's Q1 2026 earnings exceeded expectations, and management plans to submit a New Drug Application to the FDA in Q3 2026, with cash reserves expected to cover operations until 2029.
